Jeffrey Frankel

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study

Susann Varano, D. Staskin, Jeffrey Frankel, 2021, Drugs & Aging.

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial

D. Newman, Susann Varano, D. Staskin, 2022, International journal of clinical practice.

A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

M. Stölzel, Jeffrey Frankel, S. Herschorn, 2013, Urology.